Adam Feuerstein is a senior writer and biotech columnist for STAT, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a cohost of STAT's weekly "The Readout LOUD" podcast and the author of the weekly newsletter Adam's Biotech Scorecard. In 2022, a series of stories by Feuerstein and STAT colleagues that examined Biogen and the controversial approval of its Alzheimer's disease drug Aduhelm won the George Polk Award for medical reporting, and NIHCM and SABEW journalism prizes. Prior to joining STAT in 2017, Feuerstein was a longtime biotech reporter at TheStreet, a biotech analyst for a New York investment fund, and covered the early internet and dot-com era as a San Francisco-based technology reporter.
